Rafael Holdings (NYSE:RFL), the parent of Rafael Pharmaceuticals, has announced that Ashok Marin has agreed to join the company’s management team as chief legal officer. Marin will support the company’s quest to become a “fully integrated cancer metabolism therapeutics company,” Rafael Holdings said in a news release. He has previously worked for Gilead, Immunomedics, Mallinckrodt…
Biliary cancer drug candidate wins orphan drug designation from FDA
Cranbury, N.J.–based Rafael Pharmaceuticals has announced that its lead pipeline drug CPI-613 (devimistat) has won orphan drug status from FDA for biliary cancer. The orphan designation extends the orphan drug status for devimistat, including pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, Burkitt’s lymphoma, peripheral T-cell lymphomas, and soft tissue sarcoma. The Europe Medicines Agency has…